KR101389165B1 - 이치환된 프탈라진 헤지호그 （ｈｅｄｇｅｈｏｇ） 경로 길항제 - Google Patents

이치환된 프탈라진 헤지호그 （ｈｅｄｇｅｈｏｇ） 경로 길항제 Download PDF

Info

Publication number
KR101389165B1
KR101389165B1 KR1020117030157A KR20117030157A KR101389165B1 KR 101389165 B1 KR101389165 B1 KR 101389165B1 KR 1020117030157 A KR1020117030157 A KR 1020117030157A KR 20117030157 A KR20117030157 A KR 20117030157A KR 101389165 B1 KR101389165 B1 KR 101389165B1
Authority
KR
South Korea
Prior art keywords
methyl
cancer
compound
pharmaceutically acceptable
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117030157A
Other languages
English (en)
Korean (ko)
Other versions
KR20120024783A (ko
Inventor
필립 아더 힙스킨드
바빈 쿠마르 파텔
윌슨 (니 다카쿠와), 다카코
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20120024783A publication Critical patent/KR20120024783A/ko
Application granted granted Critical
Publication of KR101389165B1 publication Critical patent/KR101389165B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117030157A 2009-06-19 2010-06-15 이치환된 프탈라진 헤지호그 （ｈｅｄｇｅｈｏｇ） 경로 길항제 Expired - Fee Related KR101389165B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
US61/218,628 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
KR20120024783A KR20120024783A (ko) 2012-03-14
KR101389165B1 true KR101389165B1 (ko) 2014-04-24

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117030157A Expired - Fee Related KR101389165B1 (ko) 2009-06-19 2010-06-15 이치환된 프탈라진 헤지호그 （ｈｅｄｇｅｈｏｇ） 경로 길항제

Country Status (35)

Country Link
US (2) US8273742B2 (OSRAM)
EP (1) EP2443104B1 (OSRAM)
JP (1) JP5596139B2 (OSRAM)
KR (1) KR101389165B1 (OSRAM)
CN (1) CN102459233B (OSRAM)
AR (1) AR077014A1 (OSRAM)
AU (1) AU2010260244B2 (OSRAM)
BR (1) BRPI1011601A2 (OSRAM)
CA (1) CA2764542C (OSRAM)
CL (1) CL2011003147A1 (OSRAM)
CO (1) CO6480932A2 (OSRAM)
CR (1) CR20110658A (OSRAM)
DK (1) DK2443104T3 (OSRAM)
DO (1) DOP2011000386A (OSRAM)
EA (1) EA019059B1 (OSRAM)
EC (1) ECSP11011541A (OSRAM)
ES (1) ES2409054T3 (OSRAM)
HN (1) HN2011003139A (OSRAM)
HR (1) HRP20130408T1 (OSRAM)
IL (1) IL216599A (OSRAM)
JO (1) JO2931B1 (OSRAM)
MA (1) MA33363B1 (OSRAM)
MX (1) MX2011014029A (OSRAM)
MY (1) MY156667A (OSRAM)
NZ (1) NZ596882A (OSRAM)
PE (1) PE20121050A1 (OSRAM)
PL (1) PL2443104T3 (OSRAM)
PT (1) PT2443104E (OSRAM)
SG (1) SG177289A1 (OSRAM)
SI (1) SI2443104T1 (OSRAM)
TN (1) TN2011000627A1 (OSRAM)
TW (1) TWI385165B (OSRAM)
UA (1) UA106755C2 (OSRAM)
WO (1) WO2010147917A1 (OSRAM)
ZA (1) ZA201108587B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723042A1 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20130527T1 (en) * 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20120762T1 (hr) 2008-11-17 2012-10-31 Eli Lilly And Company Tetrasupstituirani piridazini kao inhibitori hedgehog puta
ES2446307T3 (es) * 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
AU2016271432A1 (en) * 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
EP3624798A1 (en) 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
CA3198661A1 (en) 2020-10-13 2022-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088970A2 (en) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2008110611A1 (en) 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2009002469A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (OSRAM) 1977-06-03 1981-03-07 Pfizer
JP4169368B2 (ja) 1996-01-15 2008-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脈管形成阻害性ピリダジンアミン
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
JP2003501395A (ja) 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
PT1789390E (pt) 2004-09-02 2012-02-08 Genentech Inc Inibidores de piridilo da sinalização de hedgehog
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
EP2227456A2 (en) * 2007-12-13 2010-09-15 Siena Biotech S.p.A. Hedgehog pathway antagonists and therapeutic applications thereof
CA2723042A1 (en) 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
HRP20130527T1 (en) 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20120762T1 (hr) 2008-11-17 2012-10-31 Eli Lilly And Company Tetrasupstituirani piridazini kao inhibitori hedgehog puta
ES2446307T3 (es) 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088970A2 (en) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2008110611A1 (en) 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2009002469A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
BRPI1011601A2 (pt) 2016-03-22
US9000023B2 (en) 2015-04-07
WO2010147917A1 (en) 2010-12-23
JP2012530705A (ja) 2012-12-06
DK2443104T3 (da) 2013-05-06
CA2764542A1 (en) 2010-12-23
HRP20130408T1 (en) 2013-06-30
CO6480932A2 (es) 2012-07-16
PE20121050A1 (es) 2012-08-09
IL216599A0 (en) 2012-03-01
EP2443104B1 (en) 2013-04-17
DOP2011000386A (es) 2012-02-29
TW201113268A (en) 2011-04-16
US20100324048A1 (en) 2010-12-23
MX2011014029A (es) 2012-02-21
CL2011003147A1 (es) 2012-07-20
JP5596139B2 (ja) 2014-09-24
AR077014A1 (es) 2011-07-27
NZ596882A (en) 2013-08-30
CR20110658A (es) 2012-02-20
HK1164872A1 (en) 2012-09-28
JO2931B1 (en) 2015-09-15
AU2010260244A1 (en) 2012-01-19
CA2764542C (en) 2013-09-10
ECSP11011541A (es) 2012-01-31
MY156667A (en) 2016-03-15
UA106755C2 (uk) 2014-10-10
SI2443104T1 (sl) 2013-07-31
TWI385165B (zh) 2013-02-11
US8273742B2 (en) 2012-09-25
CN102459233A (zh) 2012-05-16
ES2409054T3 (es) 2013-06-24
MA33363B1 (fr) 2012-06-01
EP2443104A1 (en) 2012-04-25
EA019059B1 (ru) 2013-12-30
ZA201108587B (en) 2013-05-29
SG177289A1 (en) 2012-02-28
AU2010260244B2 (en) 2013-09-05
PT2443104E (pt) 2013-05-07
US20120316174A1 (en) 2012-12-13
TN2011000627A1 (en) 2013-05-24
CN102459233B (zh) 2014-07-02
EA201270049A1 (ru) 2012-05-30
KR20120024783A (ko) 2012-03-14
PL2443104T3 (pl) 2013-08-30
IL216599A (en) 2015-09-24
HN2011003139A (es) 2013-07-29

Similar Documents

Publication Publication Date Title
KR101389165B1 (ko) 이치환된 프탈라진 헤지호그 （ｈｅｄｇｅｈｏｇ） 경로 길항제
KR101260116B1 (ko) 이치환된 프탈라진 헤지호그 경로 길항제
KR101342184B1 (ko) 사치환된 피리다진 헷지호그 경로 길항제
KR101335746B1 (ko) 이치환된 프탈라진 헷지호그 경로 길항제
KR101335770B1 (ko) 사치환된 피리다진 헷지호그 경로 길항제
HK1164872B (en) Disubstituted phthalazine hedgehog pathway antagonists

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200419

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200419